Protease inhibitor use among a community sample of people with HIV disease

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 20, Issue 5, 1999, Pages 474-480

  Bing, Eric G ^a   Kilbourne, Amy M ^c   Brooks, Ronald A ^b   Lazarus, Ellen F ^a   Senak, Mark ^b  

^a CHARLES R DREW UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^b AIDS Project Los Angeles   (United States)

^c Building K ^*

Author keywords

Antiviral agents; Health care utilization; HIV; Protease inhibitors

Indexed keywords

ANTIRETROVIRUS AGENT; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; DRUG USE; FEMALE; HEALTH CARE ACCESS; HEALTH CARE UTILIZATION; HEALTH SURVEY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; VIRUS INFECTION;

HUMAN IMMUNODEFICIENCY VIRUS; RNA VIRUSES;

EID: 0033560723     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199904150-00010     Document Type: Article

References (38)

1. Gazzard B. What we know so far. AIDS 1996;10:S3-S7.
2. Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral Therapy for HIV Infection in 1996. JAMA 1996;276:146-54.
3. Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1997: Updated recommendations of the International AIDS Society-USA Panel. JAMA 1997;277: 1962-9.
4. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337:734-9.
5. Detels R, Munoz A, McFarlane G, et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. JAMA 1998;280:1497-1503.
6. Centers for Disease Control. HIV/AIDS Surveillance Report. 1998;9.
7. Stein MD, Piette J, Mor V, Wachtel TJ, Fleishman J, Mayer KH, Carpenter CC. Differences in access to zidovudine (AZT) among symptomatic HIV-infected persons. J Gen Intern Med 1991;6:35-40.
8. Crystal S, Sambamoorthi U, Merzel C. The diffusion in innovation in AIDS treatment: Zidovudine use in two New Jersey cohorts. Health Serv Res 1995;30:4593-614.
9. Moore RD, Stanton D, Gopalan R, Chaisson RE. Racial differences in the use of drug therapy for HIV disease in an urban community. N Engl J Med 1994;330:763-8.
10. Graham NM, Jacobson LP, Kuo V, Chimel JS, Morgenstern H, Zucconi SL. Access to therapy in the Multicenter AIDS Cohort Study, 1989-92. J Clin Epidemiol 1994;47:1003-12.
11. Lemp GF, Hirozawa AM, Cohen JB, Derish PA, McKinney KC, Hernandez SR. Survival for women with AIDS. J Infect Dis 1992; 166:74-9.
12. Easterbrook PJ, Keruly JC, Creagh-Kirk T, Richman DD, Chaisson RE, Moore RD, Zidovudine Epidemiology Study Group. Racial and ethnic differences in outcome in zidovudine-treated patients with advanced HIV disease. JAMA 1991;266:2713-8.
13. Bright PE, Arnett DK, Blair C, Bayona M. Gender and ethnic differences in survival in a cohort of HIV positive clients. Ethn Health 1996;1:77-85.
14. Moore RD, Hidalgo J, Sugland BW, Chaisson RE. Zidovudine and the natural history of the acquired immunodeficiency syndrome. N Engl J Med 1991;324:1412-16.
15. Hu DJ, Byers RJr, Fleming PL, Ward JW. Characteristics of persons with late AIDS diagnosis in the United States. Am J Prev Med 1995;11:114-19.
16. Piette AM, Stein M, Mor V, Fleishman J, Mayer K, Wachtel T, Carpenter C. Patterns of secondary prophylaxis with aerosol pentamidine among persons with AIDS. J Acquir Immune Defic Syndr 1991;4:826-8.
17. Bing EG, Jordan W, Wyatt GE, Mitsuyasu R, Eisenberg R, Klosinski L. Factors affecting adherence to treatment among people with HIV disease. RCMI International AIDS Symposium, Puerto Rico, 1998.
18. Leppert PC, Partner SF, Thompson A. Learning from the community about barriers to health care. Obstet Gynecol 1996;87:140-1.
19. Talone P. Establishing trust after Tuskegee. Int J Radiat Oncol Biol Phys 1998;40:3-4.
20. Brawley OW. The study of untreated syphilis in the negro male. Int J Radiat Oncol Biol Phys 1998;40:5-8.
21. Gamble VN. Under the shadow of Tuskegee: African Americans and health care. Am J Public Health 1997;87:1773-8.
22. Katzenstein DA. Adherence as a particular issue with protease inhibitors. J Assoc Nurses AIDS Care 1997;1997:10-7.
23. Hirsch MS, Conway B, D'Aquila RT, et al. Antiretroviral drug resistance testing in adults with HIV infection: Implications for clinical management. International AIDS Society - USA Panel. JAMA 1998;279:1984-91.
24. Launer L, Wind A, Deeg D. Nonresponse pattern and bias in a community-based cross-sectional study of cognitive functioning among the elderly. Am J Epidemiol 1994;139:803-12.
25. Melton LJ, Dyck PJ, Karnes JL, O'Brien PC, Service FJ. Non-response bias in studies of diabetic complications: The Rochester Diabetic Neuropathy Study. J Clin Epidemiol 1993;46:341-8.
26. Sheikh K, Mattingly S. Investigating non-response bias in mail surveys. J Epidemiol Community Health 1981;35:293-6.
27. Hoeymans N, Feskens E, Van Den Bos G, Kromhout D. Non-response bias in a study of cardiovascular diseases, functional status and self-rated health among elderly men. Age Ageing 1998;27: 35-40.
28. Chou P, Kuo H, Chen C, Lin H. Characteristics of non-participants and reasons for nonparticipation in a population survey in Kin-Hu, Kinmen. Eur J Epidemiol 1997;13:195-200.
29. Strayer M, Kuthy R, Sutton S. Elderly nonrespondents to a mail survey: a telephone follow-up. Spec Care Dentist 1993;13:245-8.
30. Chavkin W, Breitbart V. Substance abuse and maternity: The United States as a case study. Addiction 1997;92:1201-5.
31. Batey RG. Denying treatment to drug and alcohol-dependent patients. Addiction 1997;92:1189-93.
32. Morrison CL, Ruben SM. The development of healthcare services for drug misusers and prostitutes. Postgrad Med J 1995;71:593-7.
33. Weissman G, Melchior L, Huba G, et al. Women living with substance abuse and HIV disease: Medical care access issues. J Am Med Womens Assoc 1995;50:115-20.
34. Poikolainen K. Alcohol and overall health outcomes. Ann Med 1996;28:381-4.
35. Horn SD. Overcoming obstacles to effective treatment: Use of clinical practice improvement methodology. J Clin Psychiatry 1997;58:15-9.
36. Boswell E, Stoudemire A. Major depression in the primary care setting. Am J Med 1996;101:3S-9S.
37. Strathdee SA, Palepu A, Cornelisse PGA, et al. Barriers to use of free antiretroviral therapy in injection drug users. JAMA 1998;280: 547-9.
38. Celentano DD, Vlahov D, Cohn S, Shadle VM, Obasanjo O, Moore RD. Self-reported antiretroviral therapy in injection drug users. JAMA 1998;280:544-6.